biostudies-literatureLuo YHMinistry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan (TW)Mayo Foundation for Medical Education and ResearchNIA NIH HHSTaipei Veterans General HospitalTaipei Veterans General Hospital (TW)Ministry of Health and WelfareNCI NIH HHSNational Institutes of HealthYin Shu-Tien Foundation Taipei Veterans General Hospital-National Yang-Ming University Excellent Physician Scientists Cultivation ProgramNational Institute on AgingNIH HHS2099-2114https://www.ebi.ac.uk/biostudies/studies/S-EPMC9945911biostudies-literatureUnknown148(8)<h4>Background</h4>The efficacy of osimertinib in previously EGFR-TKI-treated NSCLC without identification of T790M mutational status remains unclear in real-world practice.<h4>Patients and methods</h4>417 patients had stage III-IV NSCLC harboring EGFR mutation and 154 out of 417 patients receiving osimertinib as ≥ second-line EGFR-TKI were identified. The time to treatment failure and risk of death were analyzed.<h4>Results</h4>Higher risk of death was found in EGFR-mutant patients with age ≥ 65 years, non-adenocarcinoma, no surgery or radiation, non-exon 19 deletion/exon 21 L858R, higher ECOG PS (2-4), PD-L1 expression ≥ 50%, and bone/liver/adrenal metastasis (all p < 0.05). Osimertinib as ≥ second-line TKI in patients with/without identification of T790M revealed lower risk of death comJournal of cancer research and clinical oncologyReal-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation.PMC9945911MOHW109-TDU-B-211-134019R01 CA080127R03 CA077118108-2628-B-075-007 and 109-2628-B-075-023R33 AG058738108-V-A-012V108E-006-3[109] and V109C-123R01 AG052425R01 AG034676R01 AG034676 and R01 AG052425R03 CA77118, R01 CA80127 and R01 CA84354R01 CA084354Liu HLi YYang YLeventakos KPeikert TYang PWampfler JATazelaar HDLiu DLuo YHChen YMChiou SHfalseReal-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation.<h4>Background</h4>The efficacy of osimertinib in previously EGFR-TKI-treated NSCLC without identification of T790M mutational status remains unclear in real-world practice.<h4>Patients and methods</h4>417 patients had stage III-IV NSCLC harboring EGFR mutation and 154 out of 417 patients receiving osimertinib as ≥ second-line EGFR-TKI were identified. The time to treatment failure and risk of death were analyzed.<h4>Results</h4>Higher risk of death was found in EGFR-mutant patients with age ≥ 65 years, non-adenocarcinoma, no surgery or radiation, non-exon 19 deletion/exon 21 L858R, higher ECOG PS (2-4), PD-L1 expression ≥ 50%, and bone/liver/adrenal metastasis (all p < 0.05). Osimertinib as ≥ second-line TKI in patients with/without identification of T790M revealed lower risk of death com2022-01-01T00:00:00Z2022 Aug2025-04-21T16:12:47.931Z2025-04-21T16:12:47.931ZS-EPMC99459113443666710.1007/s00432-021-03766-5